Ptc Therapeutics (PTCT) Amortization of Deferred Charges (2012 - 2026)

Ptc Therapeutics' Amortization of Deferred Charges history runs 14 years deep, the most recent figure standing at $305000.0 for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges rose 2.01% year-over-year to $305000.0; the TTM figure through Mar 2026 stood at $1.2 million (up 2.0% YoY), while the FY2025 annual figure was $1.2 million, up 1.75% from the prior year.
• Amortization of Deferred Charges was $305000.0 for Q1 2026 at Ptc Therapeutics, down from $313000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $585000.0 in Q4 2022 to a low of $186000.0 in Q2 2022.
• Historically, Amortization of Deferred Charges has averaged $326411.8 across 5 years, with a median of $300000.0 in 2024.
• Biggest YoY gain for Amortization of Deferred Charges was 46.24% in 2023; the steepest drop was 48.89% in 2023.
• A 5-year view of Amortization of Deferred Charges shows it stood at $585000.0 in 2022, then sank by 48.89% to $299000.0 in 2023, then increased by 2.68% to $307000.0 in 2024, then rose by 1.95% to $313000.0 in 2025, then fell by 2.56% to $305000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $305000.0 (Q1 2026), $313000.0 (Q4 2025), and $306000.0 (Q3 2025), per Business Quant data.